CLINICAL ROLE -
Video
Author(s):
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
FDA Grants Orphan Drug Designation to AND017 for the Treatment of Sickle Cell Disease
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Removing Mesna From Cyclophosphamide Cycles in VAdriaC-IE for Ewing Sarcoma
FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors